Hypercoagulable state testing and malignancy screening following venous thromboembolic events

Vascular Medicine

Volumn 8, Issue 1, 2003, Pages 33-46

  Deitcher, Steven R ^a   Gomes, Marcelo P V ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Cancer; Diagnosis; Hypercoagulable states; Laboratory testing; Screening; Venous thrombosis

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; BLOOD CLOTTING FACTOR 5 LEIDEN; BLOOD CLOTTING FACTOR 8; DALTEPARIN; ENOXAPARIN; ESTROGEN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; METHOTREXATE; PHENYTOIN; PHOSPHOLIPID ANTIBODY; PROTHROMBIN; THEOPHYLLINE; TINZAPARIN; WARFARIN;

ACTIVATED PROTEIN C RESISTANCE; AGE; ANTICOAGULANT THERAPY; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; BLEEDING DISORDER; CANCER; CANCER SCREENING; CANCER SURVIVAL; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DRUG CHOICE; DRUG COST; DRUG MONITORING; EARLY DIAGNOSIS; FAMILY PLANNING; GENDER; HETEROZYGOSITY; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; IDIOPATHIC DISEASE; LABORATORY TEST; PRIORITY JOURNAL; PROGNOSIS; REVIEW; THROMBOEMBOLISM; TREATMENT OUTCOME; VEIN THROMBOSIS;

AGED; AGED, 80 AND OVER; FEMALE; HUMANS; MALE; MASS SCREENING; MIDDLE AGED; NEOPLASMS; PHYSICIAN'S PRACTICE PATTERNS; RISK FACTORS; THROMBOEMBOLISM; THROMBOPHILIA; VENOUS THROMBOSIS;

EID: 0038481122     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1191/1358863x03vm461ra     Document Type: Review

References (153)

1. Schafer AI. The hypercoagulable states. Ann Intern Med 1985; 102: 814-828.
2. Weinmann EE, Salzman EW. Deep-vein thrombosis. N Engl J Med 1994; 331: 1630-41.
3. Rosendaal FR. Risk factors for venous thrombotic disease. Thromb Haemost 1999; 82: 610-619.
4. Deitcher SR, Caiola E, Jaffer A. Demystifying two common genetic predispositions to venous thrombosis. Cleve Clin J Med 2000; 67: 825-36.
5. Welch GN, Loscalzo J. Homocysteine and atherothrombosis. N Engl J Med 1998; 338: 1042-50.
6. Kyrle PA, Minar E, Hirschl M et al. High plasma levels of factor VIII and the risk of recurrent venous thromboembolism. N Engl J Med 2000; 343: 457-62.
7. Anderson FA, Wheeler HB, Goldberg RJ et al. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism. The Worcester DVT Study. Arch Intern Med 1991; 151: 933-38.
8. Nordström M, Lindblad B, Bergqvist D, Kjellström T. A prospective study of the incidence of deep-vein thrombosis within a defined urban population. J Intern Med 1992; 232: 155-60.
9. Oger E, Baron N, Bressollette L et al. Incidence of venous thromboembolism: A community-based study in Western France. Thromb Haemost 2000; 83: 657-60.
10. Martinelli I, Mannucci PM, De Stefano V et al. Different risks of thrombosis in four coagulation defects associated with inherited thrombophilia: A study of 150 families. Blood 198; 92: 2353-58.
11. Simioni P, Sanson BJ, Prandoni P et al. Incidence of venous thromboembolism in families with inherited thrombophilia. Thromb Haemost 1999; 81: 198-202.
12. Van Den Belt AGM, Prins MH, Huisman MV, Hirsh J. Familial thrombophilia: A review analysis. Clin Appl Thromb Hemost 1996; 2: 227-36.
13. De Stefano V, Leone G, Mastrangelo S et al. Clinical manifestations and management of inherited thrombophilia: Retrospective analysis and follow-up after diagnosis of 238 patients with congenital deficiency of antithrombin III, protein C, protein S. Thromb Haemost 1994; 72: 352-58.
14. Pabinger I, Kyrle PA, Heistinger M, Eichinger S, Wittman E,. Lechner K. The risk of thromboembolism in asymptomatic patients with protein C and protein S deficiency: A prospective cohort study. Thromb Haemost 1994; 71: 441-45.
15. Middeldorp S, Henkens CMA, Koopman MMW et al. The incidence of venous thromboembolism in family members of patients with factor V Leiden mutation and venous thrombosis. Ann Intern Med 1998; 128: 15-20.
16. Emmerich J, Alhenc-Gelas M, Aillaud MF et al. Clinical features in 36 patients homozygous for the ARG 506 → GLN factor V mutation. Thromb Haemost 1997; 77: 620-23.
17. Schafer AI. Hypercoagulable states: Molecular genetics to clinical practice. Lancet 1994; 344: 1739-42.
18. Bauer KA. The thrombophilias: Well-defined risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-73.
19. Rosendaal FR. Risk factors for venous thrombosis: Prevalence, risk, and interaction. Semin Hematol 1997; 34: 171-87.
20. De Stefano V, Chiusolo P, Paciaroni K, Leone G. Epidemiology of factor V Leiden: Clinical implications. Semin Thromb Hemost 1998; 24: 367-79.
21. Deguchi H, Fernández JA, Pabinger I, Heit JA, Griffin JH, Plasma glucosylceramide deficiency as potential risk factor for venous thrombosis and modulator of anticoagulant protein C pathway. Blood 2001; 97: 1907-14.
22. Galli M, Ruggeri L, Barburi T. Differential effects of anti-β2-glycoprotein I and antiprothrombin antibodies on the anticoagulant activity of activated protein C. Blood 1998; 91: 1999-2004.
23. Smirnov MD, Triplett DT, Comp PC, Esmon NL, Esmon CT. On the role of phosphatidylethanolamine in the inhibition of activated protein C activity by antiphospholipid antibodies. J Clin Invest 1995; 95: 309-16.
24. Rodeghiero F, Tosetto A. Activated protein C resistance and factor V Leiden mutation are independent risk factors for venous thromboembolism. Ann Intern Med 1999; 130: 643-50.
25. Koster T, Rosendaal FR, De Ronde H, Briët E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden Thrombophilia Study. Lancet 1993; 342: 1503-06.
26. Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous for factor V Leiden (activated protein C resistance). Blood 1995; 85: 1504-08.
27. Ridker PM, Hennekens CH, Lindpaintner K, Stampfer MJ, Eisenberg PR, Miletich JP. Mutation in the gene coding for coagulation factors V and the risk of myocardial infarction, stroke, and venous thrombosis in apparently healthy men. N Engl J Med 1995; 332: 912-17.
28. Ridker PM, Hennekens CH, Selhub J, Miletich JP, Malinow MR, Stampfer MJ. Interrelation of hyperhomocyst(e)inemia factor V Leiden, and risk of future venous thromboembolism. Circulation 1997; 95: 1777-82.
29. Emmerich J, Rosendaal FR, Cattaneo M et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism: Pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Thromb Haemost 2001; 86: 809-16.
30. Gerhardt A, Scharf RE, Beckmann MW et al. Prothrombin and factor V mutations in women with a history of thrombosis during pregnancy and the puerperium. N Engl J Med 2000; 342: 374-80.
31. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oral-contraceptive users who are carriers of factor V Leiden mutation. Lancet 1994; 344: 1453-57.
32. Rosendaal FR, Vessey M, Rumley A et al. Hormonal replacement therapy, prothrombotic mutations and the risk of venous thrombosis. Br J Haematol 2002; 116: 851-54.
33. Herrington DM, Vittinghoff E, Howard TD et al. Factor V Leiden, hormone replacement therapy, and the risk of venous thromboembolic events in women with coronary disease. Arterioscler Thromb Vasc Biol 2002; 22: 1012-17.
34. Lowe G, Woodward M, Vessey M, Rumley A, Gough P, Daly E. Thrombotic variables and risk of idiopathic venous thromboembolism in women aged 45-64 years. Thromb Haemost 2000; 83: 530-35.
35. Ridker PM, Miletich JP, Stampfer MJ, Goldhaber SZ, Lindpainter K, Hennekens CH. Factor V Leiden and risks of recurrent idiopathic venous thromboembolism. Circulation 1995; 92: 2800-02.
36. 506 → Gln mutation in the gene for factor V (factor V Leiden). N Engl J Med 1997; 336: 399-403.
37. Eichinger S, Pabinger I, Stümpflen A et al. The risk of recurrent venous thromboembolism in patients with and without factor V Leiden. Thromb Haemost 1997; 77: 624-28.
38. Lindmarker P, Schulman S, Sten-Linder M, Wiman B, Egberg N, Johnsson H and the DURAC Trial Study Group. The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. Thromb Haemost 1999; 81: 684-89.
39. Kearon C, Gent M, Hirsh J et al. A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism. N Engl J Med 1999; 340: 901-907.
40. Eichinger S, Weltermann A, Mannhalter C et al. The risk of recurrent venous thromboembolism in heterozygous carriers of factor V Leiden and a first spontaneous venous thromboembolism. Arch Intern Med 2002; 162: 2357-60.
41. Rintelen C, Pabinger I, Knöbl P, Lechner K, Mannhalter Ch. Probability of recurrence of thrombosis in patients with and without factor V Leiden. Thromb Haemost 1996; 75: 229-32.
42. De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
43. Simioni P, Prandoni P, Lensing AWA et al. Risk of subsequent venous thromboembolic complications in carriers of the prothrombin or the factor V Leiden gene mutation with a first episode of deep-vein thrombosis. Blood 2000; 96: 3329-33.
44. Rintelen C, Mannhalter C, Ireland H et al. Oral contraceptives enhance the risk of clinical manifestation of venous thrombosis at a young age in females homozygous for Factor V Leiden. Br J Haematol 1996; 93: 487-90.
45. Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3′ untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698-703.
46. Rosendaal FR, Doggen CJM, Zivelin A et al. Geographic distribution of the 20210A G to A prothrombin variant. Thromb Haemost 1998; 79: 706-708.
47. 20210 gene variant. Ann Intern Med 1998; 129: 89-93.
48. Martinelli I, Taioli E, Bucciarelli P, Akhavan S, Mannucci PM. Interaction between G20210A mutation of the prothrombin gene and oral contraceptive use in deep vein thrombosis. Arterioscler Thromb Vasc Biol 1999; 19: 700-703.
49. Martinelli I, Sacchi E, Landi G, Taioli E, Duca F, Mannucci PM. High risk of cerebral vein thrombosis in carriers of a prothrombin-gene mutation and in users of oral contraceptives. N Engl J Med 1998; 338: 1793-97.
50. Zawadzki C, Gaveriaux V, Trillot N et al. Homozygous G20210A transition in the prothrombin gene associated with severe thrombotic disease: Two cases in a French family. Thromb Haemost 1998; 80: 1027-28.
51. Kyrle PA, Mannhalter C, Beguin S et al. Clinical studies and thrombin generation in patients homozygous and heterozygous for the G20210A mutation in the prothrombin gene. Arterioscler Thromb Vasc Biol 1998; 18: 1287-91.
52. De Stefano V, Martinelli I, Mannucci PM et al. The risk of recurrent venous thromboembolism among heterozygous carriers of the G20210A prothrombin gene mutation. Br J Haematol 2001; 113: 630-35.
53. Eichinger S, Minar E, Hirschl M et al. The risk of early recurrent venous thromboembolism after oral anticoagulant therapy in patients with the G20210A transition in the prothrombin gene. Thromb Haemost 1999; 81: 14-17.
54. Warshawsky I, Hren C, Sercia L et al. Detection of a novel point mutation of the prothrombin gene at position 20209. Diagn Mol Pathol 2002; 11: 152-56.
55. Alaart CF, Poort SR, Rosendaal FR, Reitsma PH, Bertina RM, Briët E. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-38.
56. Simmonds RE, Ireland H, Lane DA, Zöller B, Frutos PG, Dahlbäck B. Clarification of the risk for venous thrombosis associated with hereditary protein S deficiency by investigation of a large kindred with a characterized gene defect. Ann Intern Med 1998; 128: 8-14.
57. Hirsh J, Pionella F, Pini M. Congenital antithrombin III deficiency: Incidence and clinical features. Am J Med 1989; 87 (suppl 3B): 34S-38S.
58. Van Der Meer FJM, Koster T, Vandenbroucke JP, Briët E, Rosendaal FR. The Leiden Thrombophilia Study (LETS). Thromb Haemost 1997; 78: 631-35.
59. Miletich J, Dherman L, Broze G. Absence of thrombosis in subjects with heterozygous protein C deficiency. N Engl J Med 1987; 317: 991-96.
60. Koeleman BPC, Reitsma PH, Allart CF, Bertina RM. Activated protein C resistance as an additional risk factor for thrombosis in protein C-deficient families. Blood 1994; 84: 1031-35.
61. Koster T, Rosendaal FR, Briët E et al. Protein C deficiency in a controlled series of unselected outpatients: An infrequent but clear risk factor for venous thrombosis (Leiden Thrombophilia Study). Blood 1995; 85: 2756-61.
62. Pabinger I, Schneider B, and the GTH Study Group on Natural Inhibitors. Thrombotic risk of women with hereditary antithrombin III-, protein C- and protein S-deficiency taking oral contraceptive medication. Thromb Haemost 1994; 71: 548-52.
63. Toglia MR, Weg JG. Venous thromboembolism during pregnancy. N Engl J Med 1996; 335: 108-14.
64. Friederich PW, Sanson BJ, Simioni P et al. Frequency of pregnancy-related venous thromboembolism in anticoagulant factor-deficient women: Implications for prophylaxis. Ann Intern Med 1996; 125: 955-60.
65. Prandoni P, Lensing AWA, Cogo A et al. The long-term clinical course of acute deep venous thrombosis. Ann Intern Med 1996; 125: 1-7.
66. Van Den Belt AGM, Sanson BJ, Simioni P et al. Recurrence of venous thromboembolism in patients with familial thrombophilia. Arch Intern Med 1997; 157: 2227-32.
67. Margaglione M, D'Andrea G. Colaizzo D et al. Coexistence of factor V Leiden and factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82: 1583-87.
68. Aiach M, Borgel D, Gaussem P, Emmerich J, Alhenc-Gelas M, Gandrille S. Protein C and protein S deficiencies. Semin Hematol 1997; 34: 205-17.
69. Van Cott EM, Laposata M. Laboratory evaluation of hypercoagulable states. Hematol Oncol Clin North Am 1998; 12: 1141-66.
70. Guba SC, Fonseca V, Fink LM. Hyperhomocysteinemia and thrombosis. Semin Thromb Hemost 1999; 25: 291-309.
71. De Stefano V, Casorelli I, Rossi E, Zappacosta B, Leone G. Interaction between hyperhomocysteinemia and inherited thrombophilic factors in venous thromboembolism. Thromb Haemost 2000; 26: 305-11.
72. Den Heijer M, Koster T, Blom HJ et al. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N Engl J Med 1996; 334: 759-62.
73. Simioni P, Prandoni P, Burlina A et al. Hyperhomocysteinemia and deep-vein thrombosis: A case-control study. Thromb Haemost 1996; 76: 883-86.
74. Eichinger S, Stümpflen A, Hirschl M et al. Hyperhomocysteinemia is a risk factor of recurrent venous thromboembolism. Thromb Haemost 1998; 80: 566-69.
75. Koster T, Blann AD, Briët E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152-55.
76. Kraaijenhagen RA, Pieternella S, Anker PS et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. Thromb Haemost 2000; 83: 5-9.
77. Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82: 1024-27.
78. O'Donnel J, Mumford AD, Manning RA, Laffan M. Elevation of factor VIII:C in venous thromboembolism is persistent and independent of the acute phase response. Thromb Haemost 2000; 83: 10-13.
79. Shapiro SS. The lupus anticoagulant/antiphospholipid syndrome. Annu Rev Med 1996; 47: 533-53.
80. Love PE, Santoro SA. Antiphospholipid antibodies: Anticardiolipin and the lupus anticoagulant in systemic lupus erythematosus (SLE) and in non-SLE disorders. Ann Intern Med 1990; 112: 682-98.
81. Simioni P, Prandoni P, Zanon E et al. Deep venous thrombosis and lupus anticoagulant: A case-control study. Thromb Haemost 1996; 76: 187-89.
82. Ginsberg JS, Wells PS, Brill-Edwards P et al. Antiphospholipid antibodies and venous thromboembolism. Blood 1995; 86: 3685-91.
83. Wahl DG, Guillemin F, De Maistre E, Perret GC, Lecompte T, Thibaut G. Meta-analysis of the risk of venous thrombosis in individuals with antiphospholipid antibodies without underlying autoimmune disease or previous thrombosis. Lupus 1998; 7: 15-22.
84. Schulman S, Svenungsson E, Granqvist S, and the DURAC Study Group. Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Am J Med 1998; 104: 332-38.
85. Khamashta MA, Cuadrado MJ, Mujic F, Taub NA, Hunt BJ, Hughes GRV. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995; 332: 993-97.
86. Van Boven HH, Reitsma PH, Rosendaal FR et al. Factor V Leiden (FV R506Q) in families with inherited antithrombin deficiency. Thromb Haemost 1996; 75: 417-21.
87. Dizon-Townson D, Hutchison C, Silver R, Branch DW, Ward K. The factor V Leiden mutation which predisposes to thrombosis is not common in patients with antiphospholipid syndrome. Thromb Haemost 1995; 74: 1029-31.
88. Mandel H, Brenner B, Berant M et al. Coexistence of hereditary homocystinuria and factor V Leiden. Effect on thrombosis. N Engl J Med 1996; 334: 763-68.
89. Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol 1990; 17: 147-59.
90. Piccioli A, Prandoni P, Ewenstein BM, Goldhaber SZ. Cancer and venous thromboembolism. Am Heart J 1996; 132: 850-55.
91. Levitan N, Dowlati A, Remick SC et al. Rates of initial and recurrent thromboembolic disease among patients with malignancy versus those without malignancy: Risk analysis using Medicare claims data. Medicine 1999; 78: 285-91.
92. Hutten BA, Prins MH, Gent M, Ginsberg JS, Tijssen JGP, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: A retrospective analysis. J Clin Oncol 2000; 18: 3078-83.
93. Sarasin FP, Eckman MH. Management and prevention of thromboembolic events in patients with cancer-related hypercoagulable states: A risky business. J Gen Intern Med 1993; 8: 476-86.
94. Nordström M, Lindblad B, Anderson H, Bergqvist D, Kjellström T. Deep venous thrombosis and occult malignancy: An epidemiological study. Br Med J 1994; 308: 891-94.
95. Prandoni P, Lensing AWA, Büller HR et al. Deep-vein thrombosis and the incidence of subsequent symptomatic cancer. N Engl J Med 1992; 327: 1128-33.
96. Bastounis EA, Karayiannakis AJ, Makri GG, Alexiou D, Papalambros EL. The incidence of occult cancer in patients with deep venous thrombosis: A prospective study. J Intern Med 1996; 239: 153-56.
97. Monreal M, Fernandez-Llamazares J, Perandreu J, Urrutia A, Sahuquillo JC, Contel E. Occult cancer in patients with venous thromboembolism: Which patients, which cancers. Thromb Haemost 1997; 78: 1316-18.
98. Monreal M, Lafoz E, Casals A et al. Occult cancer in patients with deep venous thrombosis: A systematic approach. Cancer 1991; 67: 541-45.
99. Baron JA, Gridley G, Weiderpass E, Nyrén O, Linet M. Venous thromboembolism and cancer. Lancet 1998; 351: 1077-80.
100. Sørensen HT, Mellemkjær L, Steffensen FH, Olsen JH, Nielsen GL. The risk of a diagnosis of cancer after primary deep venous thrombosis or pulmonary embolism. N Engl J Med 1998; 338: 1169-73.
101. Cornuz J, Pearson SD, Creager MA, Cook EF, Goldman L. Importance of findings on the initial evaluation for cancer in patients with symptomatic idiopathic deep venous thrombosis. Ann Intern Med 1996; 125: 785-93.
102. Sørensen HT, Mellemkjær L, Olsen JH, Baron JA. Prognosis of cancers associated with venous thromboembolism. N Engl J Med 2000; 343: 1846-50.
103. Kearon C, Crowther M, Hirsh J. Management of patients with hereditary hypercoagulable disorders. Annu Rev Med 2000; 51: 169-85.
104. Hyers TM, Agnelli G, Hull RD et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S-193S.
105. Agnelli G, Prandoni P, Santamaria MG et al. Three months versus one year of oral anticoagulant therapy for idiopathic deep venous thrombosis. N Engl J Med 2001; 345: 165-69.
106. Fihn SD, Callahan CM, Martin DC, Mc Donnel MB, Henikoff JG, White RH. The risk for and severity of bleeding complications in elderly patients treated with warfarin. The National Consortium of Anticoagulation Clinics. Ann Intern Med 1996; 124: 970-79.
107. Van Den Belt AGM, Hutten BA, Prins MH, Bossuy PMM. Duration of anticoagulant treatment in patients with venous thromboembolism and a deficiency of antithrombin, protein C or protein S - A decision analysis. Thromb Haemost 2000; 84: 758-63.
108. Moll S, Ortel TL. Monitoring warfarin therapy in patients with lupus anticoagulants. Ann Intern Med 1997; 127: 177-85.
109. Levine JS, Branch DW, Rauch J. The antiphospholipid syndrome. N Engl J Med 2002; 346: 752-63.
110. Deitcher SR, Carman TL, Sheikh MA, Gomes MPV. Hypercoagulable Syndromes: Evaluation and management strategies for acute limb ischemia. Semin Vasc Surg 2001; 14: 74-85.
111. Van Boven HH, Lane DA. Antithrombin and its inherited deficiency states. Semin Hematol 1997; 34: 188-204.
112. Van Boven HH, Vandenbroucke JP, Westendorp RGJ, Rosendaal FR. Mortality and causes of death in inherited antithrombin deficiency. Thromb Haemost 1997; 452-55.
113. Rosendaal FR, Heijboer H, Briët E, et al. Mortality in hereditary antithrombin-III deficiency: 1830 to 1989. Lancet 1991; 337: 260-62.
114. Rosendaal FR, Helmerhorst FM, Vandenbroucke JP. Female hormones and thrombosis. Arterioscler Thromb Vasc Biol 2002; 22: 201-10.
115. Vandenbroucke JP, Van Der Meer FJM, Helmerhorst FM, Rosendaal FR. Factor V Leiden: Should we screen oral contraceptive users and pregnant women? BMJ 1996; 313: 1127-30.
116. Vandenbroucke JP, Rosing J, Bloemenkamp KWM et al. Oral contraceptives and the risk of venous thrombosis. N Engl J Med 2001; 344: 1527-35.
117. World Health Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Cardiovascular disease and use of oral and injectable progestogen-only contraceptives and combined injectable contraceptives. Contraception 1998; 57: 315-24.
118. Vasilakis C, Jick H, Melero-Montes MM. Risk of idiopathic venous thromboembolism in users of progestogens alone. Lancet 1999; 354: 1610-11.
119. Høibraaten E, Ovigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy: Results of the randomized, doubleblind, placebo-controlled Estrogen in Venous Thromboembolism Trial (EVTET). Thromb Haemost 2000; 84: 961-67.
120. Bauer KA. Hormone replacement therapy and the factor V Leiden mutation. Arterioscler Thromb Vasc Biol 2002; 22: 879-80.
121. Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119: 122S-31S.
122. Brill-Edwards P, Ginsberg JS, Gent M et al. Safety of withholding heparin in pregnant women with a history of venous thromboembolism. N Engl J Med 2000; 343: 1439-44.
123. Wilson WA, Gharavi AE, Koike T et al. International consensus statement on preliminary classification criteria for definite antiphospholipid syndrome. Arthritis Rheum 1999; 42: 1309-11.
124. Kutteh WH, Park VM, Deitcher SR. Hypercoagulable state mutation analysis in white patients with early first-trimester recurrent pregnancy loss. Fertil Steril 1999; 71: 1048-53.
125. Kutteh WH. Antiphospholipid antibody-associated recurrent pregnancy loss: Treatment with heparin and low-dose aspirin is superior to low-dose aspirin alone. Am J Obstet Gynecol 1996; 174: 1584-89.
126. Subar M. Clinical evaluation of hypercoagulable states. Clin Geriatr Med 2001; 17: 57-70.
127. Deitcher SR, Volner JS, Kottke-Marchant K. Activated protein C resistance (APC-R) and elevated factor VIII (FVIII) activity associated interference in functional protein S assays. Blood 1998; 92 (suppl 1): 131b.
128. Brandt JT, Triplett DA, Alving B, Scharrer I. Criteria for the diagnosis of lupus anticoagulants: An update. Thromb Haemost 1995; 74: 1185-90.
129. Socié G, Mary JY, Gramont A et al. Paroxysmal Nocturnal Haemoglobinuria: Long-term follow-up and prognostic factors. Lancet 1996; 348: 573-77.
130. Hillmen P, Lewis SM, Bressler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med 1995; 333: 1253-58.
131. Gruppo Italiano Studio Policitemia. Polycythemia vera: The natural history of 1213 patients followed for 20 years. Ann Intern Med 1995; 123: 656-64.
132. Berk PD, Goldberg JD, Donovan PB, Fruchtman SM, Berlin NI, Wasserman LR. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-43.
133. Cortelazzo S, Viero P, Finazzi G, D'Emilio A, Rodeghiero F, Barbui T. Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia. J Clin Oncol 1990; 8: 556-62.
134. Faioni EM, Franchi F, Asti D, Sacchi E, Bernardi F, Mannucci PM. Resistance to activated protein C in nine thrombophilic families: Interference in a protein S functional assay. Thromb Haemost 1993; 70: 1067-71.
135. Stahl CP, Wideman CS, Spira TJ et al. Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 1993; 81: 1801-07.
136. Deitcher SR, Schulman S, Lindmarker P. Significance of early natural anticoagulant activity testing for the risk of venous thromboembolism recurrence. Thromb Haemost 2001 (suppl): abstr P2950
137. Smith RA, Cokkinides V, Eyre HJ. American Cancer Society guidelines for the early detection of cancer, 2003. CA Cancer J Clin 2003; 53: 27-43.
138. Levine MN, Lee AYY. Treatment of venous thromboembolism in cancer patients. Semin Thromb Hemost 1999; 25: 245-49.
139. Lensing AWA, Prins MH, Davidson BL, Hirsh J. Treatment of deep venous thrombosis with low-molecular-weight heparins. Arch Intern Med 1995; 155: 601-607.
140. Siragusa S, Cosmi B, Piovella F, Hirsh J, Ginsberg JS. Low-molecular-weight heparins and unfractionated heparin in the treatment of patients with acute venous thromboembolism: Results of a meta-analysis. Am J Med 1996; 100: 269-77.
141. Gould MK, Dembitzer AD, Doyle RL, Hastie TJ, Garber AM. Low-molecular-weight heparins compared with unfractionated heparin for treatment of acute deep venous thrombosis: A meta-analysis of randomized, controlled trials. Ann Intern Med 1999; 130: 800-809.
142. Dolovich LR, Ginsberg JS, Douketis JD, Holbrook AM, Cheah G. A meta-analysis comparing low-molecular-weight heparins with unfractionated heparin in the treatment of venous thromboembolism: Examining some unanswered questions regarding location of treatment, product type, and dosing frequency. Arch Intern Med 2000; 160: 181-88.
143. Ridker PM, Miletich JP, Henneckens CH, Buring JE. Ethnic distribution of factor V Leiden in 4047 men and women: Implications for venous thromboembolism screening. J Am Med Assoc 1997; 277: 1305-307.
144. Griffin JH, Evatt B, Wideman C, Fernández JA. Anticoagulant protein C pathway defective in majority of thrombophilic patients. Blood 1993; 82: 1989-93.
145. Ben Tal O, Zinelin A, Seligsohn U. The relative frequency of hereditary thrombotic disorders among 107 patients with thrombophilia in Israel. Thromb Haemost 1989; 61: 50-54.
146. Tait RC, Walker ID, Perry DJ et al. Prevalence of antithrombin deficiency in the healthy population. Br J Haematol 1994; 87: 106-12.
147. Shi W, Krilis SA, Chong BH, Gordon S, Chesterman CN. Prevalence of lupus anticoagulant and anticardiolipin antibodies in a healthy population. Aust NZ J Med 1990; 20: 231-36.
148. Vila P, Hernández MC, López-Fernández MF, Battle J. Prevalence, follow-up and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 1994; 72: 209-13.
149. Ridker PM, Goldhaber SZ, Danielson E et al. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003; 348: 1425-34.
150. Rassow JE, Anderson GL, Prentice RL et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: Principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002; 288: 321-33.
151. Levine MN, Lee AY, Baker RI et al. A randomized trial of long term dalteparin low molecular weight heparin versus oral anticoagulant therapy in cancer patients with venous thromboembolism. Blood 2002; 100: 82a.
152. Hull RD, Pineo GF, Mah AF, Brant RF. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood 2002; 100: 148a.
153. Deitcher SR, Kessler CM, Merli G et al. Secondary prevention of venous thromboembolic events in patients with active malignancy: A randomized study of enoxaparin sodium alone versus initial enoxaparin sodium followed by warfarin for a 180-day period. Proc Am Soc Clin Oc 2003 In press.